Empowered Patient Podcast

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the application of AI for administrative and clinical uses, the changing dynamic between doctors and patients, personalized medicine, cell and gene therapies, aging in place, wearables and sensors, clinical trials and advances in clinical research, payer trends, transparency in the medical marketplace and challenges for connected health entrepreneurs. This show continues to evolve driven by the convergence of a diverse array of industries.

Microwave Ablation Provides Minimally Invasive Treatment Option for Benign Thyroid Nodules with Mark Saxton Baird Medical TRANSCRIPT 07/20/2026

Microwave Ablation Provides Minimally Invasive Treatment Option for Benign Thyroid Nodules with Mark Saxton Baird Medical TRANSCRIPT Mark Saxton, CEO of Baird Medical, highlights their microwave ablation technology, which is being used to address a significant treatment gap for benign thyroid nodules. This minimally invasive approach is an alternative to radiofrequency ablation, accommodates patients with pacemakers or other cardiac devices, and provides faster recovery. Unlike surgery, microwave ablation preserves thyroid function, eliminating the need for ongoing hormone replacement therapy Mark explains, "It's very interesting that we're focused on thyroid tumors because they're an extremely prevalent issue. Most of those tumors are benign, and for many of those patients, active surveillance, or what we call watchful waiting, is appropriate. But a portion of those may need more than that. Their nodules are growing, they're becoming symptomatic either cosmetically or they're compressing on their throat, and that becomes extremely bothersome for them." "A minimally invasive option, like a microwave, may be more appropriate for those patients than a surgery would be. The bottom line is there's still a huge gap between diagnosis and treatment, and that's an exciting problem for us to want to solve." "So surgery is extremely safe and very appropriate in many patients, but there is a scar, it's a surgery, you're under general anesthetic. The other thing that surgery does is if we do a thyroidectomy, we may be destroying the thyroid's ability, obviously, then to provide the hormones, T3 and T4, that regulate some of our metabolism. So with the microwave, we just destroy the nodule. We don't impact thyroid function in that way, so patients don't need that hormone replacement. So that's another great reason to move forward with something more minimally invasive." #BairdMedical #MicrowaveAblation #ThyroidMWA #MWA #ThyroidCare #ThyroidNodules #MinimallyInvasive #InterventionalEndocrinology #Endocrinology #PatientCare #MedicalDevices /episode/index/show/empoweredpatient/id/42048940

Microwave Ablation Provides Minimally Invasive Treatment Option for Benign Thyroid Nodules with Mark Saxton Baird Medical 07/20/2026

Microwave Ablation Provides Minimally Invasive Treatment Option for Benign Thyroid Nodules with Mark Saxton Baird Medical Mark Saxton, CEO of Baird Medical, highlights their microwave ablation technology, which is being used to address a significant treatment gap for benign thyroid nodules. This minimally invasive approach is an alternative to radiofrequency ablation, accommodates patients with pacemakers or other cardiac devices, and provides faster recovery. Unlike surgery, microwave ablation preserves thyroid function, eliminating the need for ongoing hormone replacement therapy Mark explains, "It's very interesting that we're focused on thyroid tumors because they're an extremely prevalent issue. Most of those tumors are benign, and for many of those patients, active surveillance, or what we call watchful waiting, is appropriate. But a portion of those may need more than that. Their nodules are growing, they're becoming symptomatic either cosmetically or they're compressing on their throat, and that becomes extremely bothersome for them." "A minimally invasive option, like a microwave, may be more appropriate for those patients than a surgery would be. The bottom line is there's still a huge gap between diagnosis and treatment, and that's an exciting problem for us to want to solve." "So surgery is extremely safe and very appropriate in many patients, but there is a scar, it's a surgery, you're under general anesthetic. The other thing that surgery does is if we do a thyroidectomy, we may be destroying the thyroid's ability, obviously, then to provide the hormones, T3 and T4, that regulate some of our metabolism. So with the microwave, we just destroy the nodule. We don't impact thyroid function in that way, so patients don't need that hormone replacement. So that's another great reason to move forward with something more minimally invasive." #BairdMedical #MicrowaveAblation #ThyroidMWA #MWA #ThyroidCare #ThyroidNodules #MinimallyInvasive #InterventionalEndocrinology #Endocrinology #PatientCare #MedicalDevices /episode/index/show/empoweredpatient/id/42048930

Open-Source Focused Ultrasound and Infrared MedTech to Advance Stroke Diagnosis and Neurological Therapies Aaron Timm Openwater TRANSCRIPT 07/16/2026

Open-Source Focused Ultrasound and Infrared MedTech to Advance Stroke Diagnosis and Neurological Therapies Aaron Timm Openwater TRANSCRIPT Aaron Timm, CEO of Openwater, is driving the shift from single-purpose, room-sized equipment to multi-purpose, portable, light-weight medical devices designed on an open-source platform. Some tools use infrared light to measure blood flow in real time for applications such as stroke detection. Another device uses focused ultrasound to modulate tissue in the brain for treating neurodegenerative diseases and psychiatric conditions. The platform is designed so that a single hardware device can run multiple applications, allowing researchers to adapt and develop applications specific to their work, bringing innovation into the marketplace similar to the smartphone app environment. Aaron explains, "So we have two primary devices. One uses infrared light to measure blood flow and blood volume in real time. So that one is being used, for example, to measure blood flow to the brain to help determine whether someone is having a stroke. At the University of Pennsylvania, there was a study done using that device, where our device outperformed the existing stroke scales. The other device that we have is a focused ultrasound device. And what that device does is it uses sound waves or focused ultrasound to target and modulate tissue in the brain and elsewhere in the body. That's being used in research today for all sorts of neurodegenerative diseases, psychiatric diseases. And there's just a lot going on in the world of focused ultrasound, including using our devices." "So this focused ultrasound device and the science behind it eliminates the need for drugs or surgery and just uses focused ultrasounds to modulate or stimulate things within the brain, for example. It's used for everything from depression, anxiety, Alzheimer's disease, and addiction. Many different indications are being addressed in research using these kinds of devices, including ours." #OpenwaterHealth #MedTech, #NonInvasiveCare, #PortableHealthcare, #PatientAccess, #HealthcareInnovation #FocusedUltrasound #LIFU #Hemodynamics #Openwater #OpenLIFU #OpenMotion #DigitalHealth #Neurotechnology #StrokeCare #AIinHealthcare #OpenSourceMedicine #ClinicalResearch #WearableMedicalDevices #HealthcareInnovation /episode/index/show/empoweredpatient/id/42000940

Open-Source Focused Ultrasound and Infrared MedTech to Advance Stroke Diagnosis and Neurological Therapies Aaron Timm Openwater 07/16/2026

Open-Source Focused Ultrasound and Infrared MedTech to Advance Stroke Diagnosis and Neurological Therapies Aaron Timm Openwater Aaron Timm, CEO of Openwater, is driving the shift from single-purpose, room-sized equipment to multi-purpose, portable, light-weight medical devices designed on an open-source platform. Some tools use infrared light to measure blood flow in real time for applications such as stroke detection. Another device uses focused ultrasound to modulate tissue in the brain for treating neurodegenerative diseases and psychiatric conditions. The platform is designed so that a single hardware device can run multiple applications, allowing researchers to adapt and develop applications specific to their work, bringing innovation into the marketplace similar to the smartphone app environment. Aaron explains, "So we have two primary devices. One uses infrared light to measure blood flow and blood volume in real time. So that one is being used, for example, to measure blood flow to the brain to help determine whether someone is having a stroke. At the University of Pennsylvania, there was a study done using that device, where our device outperformed the existing stroke scales. The other device that we have is a focused ultrasound device. And what that device does is it uses sound waves or focused ultrasound to target and modulate tissue in the brain and elsewhere in the body. That's being used in research today for all sorts of neurodegenerative diseases, psychiatric diseases. And there's just a lot going on in the world of focused ultrasound, including using our devices." "So this focused ultrasound device and the science behind it eliminates the need for drugs or surgery and just uses focused ultrasounds to modulate or stimulate things within the brain, for example. It's used for everything from depression, anxiety, Alzheimer's disease, and addiction. Many different indications are being addressed in research using these kinds of devices, including ours." #OpenwaterHealth #MedTech, #NonInvasiveCare, #PortableHealthcare, #PatientAccess, #HealthcareInnovation #FocusedUltrasound #LIFU #Hemodynamics #Openwater #OpenLIFU #OpenMotion #DigitalHealth #Neurotechnology #StrokeCare #AIinHealthcare #OpenSourceMedicine #ClinicalResearch #WearableMedicalDevices #HealthcareInnovation /episode/index/show/empoweredpatient/id/42000925

Multi-Target T Cell Engagers Transforming Treatment for Solid Tumors with Jack Silberstein Deck Bio TRANSCRIPT 07/16/2026

Multi-Target T Cell Engagers Transforming Treatment for Solid Tumors with Jack Silberstein Deck Bio TRANSCRIPT Jack Silberstein, CEO of Deck Bio, is developing next-generation T cell engagers designed to activate the patient's immune system to shrink tumors. These T cell engagers are bispecific molecules that alert immune cells to recognize targets on cancer cells and kill them by binding to both the cancer cells and the T cells. While earlier T cell engagers have succeeded in treating blood cancers, Deck Bio focuses on solid tumors where previous approaches have failed. Their lead molecule demonstrates strong potency and high safety, showing a response in patients with treatment resistance across lung, gastric, esophageal, liver, and head and neck cancers. Jack explains, "At Deck Bio, we're focused on next-generation cancer immunotherapies called T cell engagers and are working to engage a patient's immune response to shrink tumors, extend patients' lifespan, and deliver durable benefits in treating cancer. For T cell engagers, there's been a lot of excitement recently because, in 2022, we had the first-ever T cell engager approved for solid tumors. We're looking to build on these learnings, expand the reach of T cell engagers, and drive greater durable benefit." "As you mentioned, these T cell engagers have been around for a while. With liquid tumors, there's a little bit of an easier problem to solve because, in terms of the cancer cells there, you're able to deplete them, and if you have any type of healthy tissue recognition of cells in your blood, that's not that terrible of a toxicity." "But in solid tumors, there's been a lot of failures in the field where people have tried to develop something against a solid tumor target that they thought was cancer-specific. Then, because of expression on other healthy tissues throughout the body, there were these dose-limiting toxicities. And just to level set in terms of what a T cell engager is, and help explain that, it's a bispecific molecule. What it most typically looks like is what people think of as an antibody, with that classical Y shape." #DeckBio #TCellEngagers #Immunotherapy #Solidtumors #TumorHeterogeneity #ImmunoOncology #TCellEngagers #SolidTumors #CancerImmunotherapy #OncologyInnovation #MultiTargetTherapy #HemOnc /episode/index/show/empoweredpatient/id/42000865

Multi-Target T Cell Engagers Transforming Treatment for Solid Tumors with Jack Silberstein Deck Bio 07/16/2026

Multi-Target T Cell Engagers Transforming Treatment for Solid Tumors with Jack Silberstein Deck Bio Jack Silberstein, CEO of Deck Bio, is developing next-generation T cell engagers designed to activate the patient's immune system to shrink tumors. These T cell engagers are bispecific molecules that alert immune cells to recognize targets on cancer cells and kill them by binding to both the cancer cells and the T cells. While earlier T cell engagers have succeeded in treating blood cancers, Deck Bio focuses on solid tumors where previous approaches have failed. Their lead molecule demonstrates strong potency and high safety, showing a response in patients with treatment resistance across lung, gastric, esophageal, liver, and head and neck cancers. Jack explains, "At Deck Bio, we're focused on next-generation cancer immunotherapies called T cell engagers and are working to engage a patient's immune response to shrink tumors, extend patients' lifespan, and deliver durable benefits in treating cancer. For T cell engagers, there's been a lot of excitement recently because, in 2022, we had the first-ever T cell engager approved for solid tumors. We're looking to build on these learnings, expand the reach of T cell engagers, and drive greater durable benefit." "As you mentioned, these T cell engagers have been around for a while. With liquid tumors, there's a little bit of an easier problem to solve because, in terms of the cancer cells there, you're able to deplete them, and if you have any type of healthy tissue recognition of cells in your blood, that's not that terrible of a toxicity." "But in solid tumors, there's been a lot of failures in the field where people have tried to develop something against a solid tumor target that they thought was cancer-specific. Then, because of expression on other healthy tissues throughout the body, there were these dose-limiting toxicities. And just to level set in terms of what a T cell engager is, and help explain that, it's a bispecific molecule. What it most typically looks like is what people think of as an antibody, with that classical Y shape." #DeckBio #TCellEngagers #Immunotherapy #Solidtumors #TumorHeterogeneity #ImmunoOncology #TCellEngagers #SolidTumors #CancerImmunotherapy #OncologyInnovation #MultiTargetTherapy #HemOnc /episode/index/show/empoweredpatient/id/42000850

Building an AI and Data-Driven Holistic View of Patient Health with Professor Linda Macomber Renaissance Health TRANSCRIPT 07/15/2026

Building an AI and Data-Driven Holistic View of Patient Health with Professor Linda Macomber Renaissance Health TRANSCRIPT Professor Linda Macomber, a healthcare tech consultant at Renaissance Health, highlights the transformative potential of AI and digital health solutions, as well as the shift from siloed, symptom-focused care to holistic, personalized medicine. AI applications in healthcare have moved from deterministic expert systems to generative AI models that use genomic and longitudinal data from wearables for continuous monitoring and preventive care. Linda emphasizes that successful AI implementation requires viewing technology as a strategic investment rather than an expense, with a focus on actions that improve patient outcomes and clinicians' quality of life. Linda explains, "Well, I've certainly been involved in all areas of the healthcare ecosystem over the past 40 years. For the past 16 years, I have been a professor at National University, starting the Master of Science and Health Informatics program. The 30 years prior to that, working in different areas of software design and development in the early days with SAIC and the Department of Defense, then Kaiser Permanente, University of California systems, and then some work with community health centers as well. I'm a life fellow in HIMSS, which is only a few people who have been around long enough to have that designation. But started my career as an ICU nurse and still hold on to the clinical informatics side, look at it from the lens of a healthcare professional, as well as the tech, educator, and startup perspective. Most recently, I have been working with a number of different startups." "Well, certainly when it comes to the opportunities with AI in particular, things are moving so fast and looking at lots of different priorities and opportunities. When it comes to incremental change, it is always a little easier, but I think that opportunities are much bigger now for much more significant advancement of the care delivery system. Bringing care to people instead of people always having to travel to facilities for care, using digital systems in new ways to empower all of us, informing choice, and being much more proactive and personalized." #LindaMacomber #HealthcareInnovation #DigitalHealth #HealthInformatics #AIinHealthcare #ClinicalInformatics #Genomics #Wearables #PopulationHealth #Interoperability #MedicalEducation /episode/index/show/empoweredpatient/id/42000780

Building an AI and Data-Driven Holistic View of Patient Health with Professor Linda Macomber Renaissance Health 07/15/2026

Building an AI and Data-Driven Holistic View of Patient Health with Professor Linda Macomber Renaissance Health Professor Linda Macomber, a healthcare tech consultant at Renaissance Health, highlights the transformative potential of AI and digital health solutions, as well as the shift from siloed, symptom-focused care to holistic, personalized medicine. AI applications in healthcare have moved from deterministic expert systems to generative AI models that use genomic and longitudinal data from wearables for continuous monitoring and preventive care. Linda emphasizes that successful AI implementation requires viewing technology as a strategic investment rather than an expense, with a focus on actions that improve patient outcomes and clinicians' quality of life. Linda explains, "Well, I've certainly been involved in all areas of the healthcare ecosystem over the past 40 years. For the past 16 years, I have been a professor at National University, starting the Master of Science and Health Informatics program. The 30 years prior to that, working in different areas of software design and development in the early days with SAIC and the Department of Defense, then Kaiser Permanente, University of California systems, and then some work with community health centers as well. I'm a life fellow in HIMSS, which is only a few people who have been around long enough to have that designation. But started my career as an ICU nurse and still hold on to the clinical informatics side, look at it from the lens of a healthcare professional, as well as the tech, educator, and startup perspective. Most recently, I have been working with a number of different startups." "Well, certainly when it comes to the opportunities with AI in particular, things are moving so fast and looking at lots of different priorities and opportunities. When it comes to incremental change, it is always a little easier, but I think that opportunities are much bigger now for much more significant advancement of the care delivery system. Bringing care to people instead of people always having to travel to facilities for care, using digital systems in new ways to empower all of us, informing choice, and being much more proactive and personalized." #LindaMacomber #HealthcareInnovation #DigitalHealth #HealthInformatics #AIinHealthcare #ClinicalInformatics #Genomics #Wearables #PopulationHealth #Interoperability #MedicalEducation /episode/index/show/empoweredpatient/id/42000745

DNA Sequencing Tests Identify Causes of Infections in Immunocompromised Patients with Alec Ford Karius TRANSCRIPT 07/14/2026

DNA Sequencing Tests Identify Causes of Infections in Immunocompromised Patients with Alec Ford Karius TRANSCRIPT Alec Ford, CEO of Karius, has developed an innovative approach to diagnosing infections in immunocompromised patients, using DNA sequencing of blood samples to identify over 1,300 causes of infection within 24 hours. Traditional diagnostic methods rely on hypothesis-driven testing and the cultivation of organisms. At the same time, the Karius approach enables faster, more targeted antibiotic treatment, reduces unnecessary broad-spectrum antibiotics, and can identify infections that may not be included in the initial diagnosis. Time to proper treatment is essential for vulnerable populations, including cancer patients, HIV-positive individuals, organ transplant recipients, and those undergoing autoimmune therapies. Alec explains, "These are patients going through cancer treatment, patients with HIV, people going through solid organ transplantation, or people being treated assertively with autoimmune therapies for autoimmune disorders, where it may compromise their immune system. That really vulnerable patient is our exclusive focus as a company." "So, a patient gets admitted to the hospital for an infection. They take a sample of that patient's blood. And what we can do is diagnose over 1,300 causes of infection by sequencing the patient's blood for viruses, parasites, bacteria, and fungi that could threaten the success of their cancer treatment or solid organ transplant. There's never been a test in the history of infectious disease that can test for any DNA-based organism, and we do so. We can return a result 24 hours after we receive the sample." #Karius #InfectiousDisease #Diagnostics #Metagenomics #MedTech #KariusSpectrum #KariusFocus #NextGenSequencing #ImmunocompromisedCare #Oncology #TransplantMedicine #AntimicrobialStewardship #Genomics #MolecularDiagnostics #KariusTest #PatientSafety #HealthcareInnovation /episode/index/show/empoweredpatient/id/42000660

DNA Sequencing Tests Identify Causes of Infections in Immunocompromised Patients with Alec Ford Karius 07/14/2026

DNA Sequencing Tests Identify Causes of Infections in Immunocompromised Patients with Alec Ford Karius Alec Ford, CEO of Karius, has developed an innovative approach to diagnosing infections in immunocompromised patients, using DNA sequencing of blood samples to identify over 1,300 causes of infection within 24 hours. Traditional diagnostic methods rely on hypothesis-driven testing and the cultivation of organisms. At the same time, the Karius approach enables faster, more targeted antibiotic treatment, reduces unnecessary broad-spectrum antibiotics, and can identify infections that may not be included in the initial diagnosis. Time to proper treatment is essential for vulnerable populations, including cancer patients, HIV-positive individuals, organ transplant recipients, and those undergoing autoimmune therapies. Alec explains, "These are patients going through cancer treatment, patients with HIV, people going through solid organ transplantation, or people being treated assertively with autoimmune therapies for autoimmune disorders, where it may compromise their immune system. That really vulnerable patient is our exclusive focus as a company." "So, a patient gets admitted to the hospital for an infection. They take a sample of that patient's blood. And what we can do is diagnose over 1,300 causes of infection by sequencing the patient's blood for viruses, parasites, bacteria, and fungi that could threaten the success of their cancer treatment or solid organ transplant. There's never been a test in the history of infectious disease that can test for any DNA-based organism, and we do so. We can return a result 24 hours after we receive the sample." #Karius #InfectiousDisease #Diagnostics #Metagenomics #MedTech #KariusSpectrum #KariusFocus #NextGenSequencing #ImmunocompromisedCare #Oncology #TransplantMedicine #AntimicrobialStewardship #Genomics #MolecularDiagnostics #KariusTest #PatientSafety #HealthcareInnovation /episode/index/show/empoweredpatient/id/42000640

Rapid Exome and Genome Testing for the Diagnosis of Rare Diseases with Lisa Gurry GeneDx TRANSCRIPT 07/13/2026

Rapid Exome and Genome Testing for the Diagnosis of Rare Diseases with Lisa Gurry GeneDx TRANSCRIPT Lisa Gurry, Chief Business Officer at GeneDx, is transforming the diagnosis of rare diseases in children by providing comprehensive genetic testing. Using exome and genome sequencing, they deliver rapid, accurate results that enable early intervention and access to therapies. Through partnerships and a network of genetic counselors, GeneDx connects patients with specialists and clinical trials to ensure equal access for children and has established a comprehensive database that supports clinical care and drug development and helps identify previously undiagnosed or misdiagnosed conditions. Lisa explains, "The average diagnostic odyssey, or the time it takes to get a diagnosis, is tragically far too long for most families. It can take five years or more to get that diagnosis. And it's typically because the system tends to wait and see to provide the genetic tests that could give a diagnosis very quickly. At GeneDX, we've focused on exome and genome testing, which enables us to have a very comprehensive view across variants of potential diagnoses. And so that's our recommendation: any family that is experiencing a developmental delay has concerns with epilepsy, autism, or any number of genetic potential conditions. The beautiful part about a genetic test is that it can give you the answer you need to know what action to take." "It's remarkable how much science and technology have evolved. So we did our first exome test in 2011, and since then we've sequenced over one million exomes and genomes. So, a tremendous amount of progress has been made in the number of children that we've diagnosed. That's possible because science and technology have advanced, the cost of the test has dramatically reduced, and our ability to deliver that at scale is something that we've been investing in for the last 25 years." #GeneDx #RareDisease #Genomics #Pediatrics #PrecisionMedicine #GeneticTesting #Epilepsy #GeneTherapy #RealWorldData #Biopharma #ClinicalTrials #HealthcareInnovation /episode/index/show/empoweredpatient/id/42000535

Rapid Exome and Genome Testing for the Diagnosis of Rare Diseases with Lisa Gurry GeneDx 07/13/2026

Rapid Exome and Genome Testing for the Diagnosis of Rare Diseases with Lisa Gurry GeneDx Lisa Gurry, Chief Business Officer at GeneDx, is transforming the diagnosis of rare diseases in children by providing comprehensive genetic testing. Using exome and genome sequencing, they deliver rapid, accurate results that enable early intervention and access to therapies. Through partnerships and a network of genetic counselors, GeneDx connects patients with specialists and clinical trials to ensure equal access for children and has established a comprehensive database that supports clinical care and drug development and helps identify previously undiagnosed or misdiagnosed conditions. Lisa explains, "The average diagnostic odyssey, or the time it takes to get a diagnosis, is tragically far too long for most families. It can take five years or more to get that diagnosis. And it's typically because the system tends to wait and see to provide the genetic tests that could give a diagnosis very quickly. At GeneDX, we've focused on exome and genome testing, which enables us to have a very comprehensive view across variants of potential diagnoses. And so that's our recommendation: any family that is experiencing a developmental delay has concerns with epilepsy, autism, or any number of genetic potential conditions. The beautiful part about a genetic test is that it can give you the answer you need to know what action to take." "It's remarkable how much science and technology have evolved. So we did our first exome test in 2011, and since then we've sequenced over one million exomes and genomes. So, a tremendous amount of progress has been made in the number of children that we've diagnosed. That's possible because science and technology have advanced, the cost of the test has dramatically reduced, and our ability to deliver that at scale is something that we've been investing in for the last 25 years." #GeneDx #RareDisease #Genomics #Pediatrics #PrecisionMedicine #GeneticTesting #Epilepsy #GeneTherapy #RealWorldData #Biopharma #ClinicalTrials #HealthcareInnovation /episode/index/show/empoweredpatient/id/42000515

Combating AMR with Cutting-Edge Antimicrobials That Outsmart Multidrug-Resistant Bacteria with Kelvin Cooper Lakewood-Amedex TRANSCRIPT 07/09/2026

Combating AMR with Cutting-Edge Antimicrobials That Outsmart Multidrug-Resistant Bacteria with Kelvin Cooper Lakewood-Amedex TRANSCRIPT Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics, has developed a novel class of antimicrobials that operate by disrupting bacterial and fungal cell membranes, rapidly killing the microorganisms. Traditional antimicrobials work by inhibiting bacterial growth, but bacteria have evolved resistance mechanisms against all drug classes, with multidrug-resistant strains becoming increasingly common. The company is focused on treating infected diabetic foot ulcers with a topical gel formulation that locally delivers a high drug concentration while minimizing systemic side effects. Kelvin explains, "You can go back all the way to the discovery of penicillin a century ago, and there was tremendous excitement around that. And then through the 40s, when they figured out how to deep tank ferment the antibacterials, the beta lactams, as it was then, again, there was no real indication that resistance was going to be that big of a problem." "What we have done at Lakewood-Amedex Biotherapeutics is we've discovered a completely new class of antimicrobials, and it's probably good to give some context of how most antimicrobials work. Typically, what they do is they will stop the bacteria from dividing and growing, and that prevents the bacteria from causing an infection. Now the bacteria and fungi have figured out ways to mutate around that. So they have a different way of building cell walls, for example. And that has become the big problem. Our class of agents hits a completely different type of mechanism. We believe that what happens, and we have good scientific data to show this, is that this class of agents attacks the membrane of bacteria and fungi. It disrupts the membrane, which allows the contents of whatever microbe it is to spill out, and it immediately kills the bacteria extremely rapidly." #LakewoodAmedex #AntimicrobialResistance #AMR #InfectiousDiseases #Antibiotics #Antimicrobials #DiabeticFoot #DiabeticFootUlcer #HealthcareInnovation #DiabeticCare #Biotech #PublicHealth #MedicalBreakthrough $LABT /episode/index/show/empoweredpatient/id/41913385

Combating AMR with Cutting-Edge Antimicrobials That Outsmart Multidrug-Resistant Bacteria with Kelvin Cooper Lakewood-Amedex 07/09/2026

Combating AMR with Cutting-Edge Antimicrobials That Outsmart Multidrug-Resistant Bacteria with Kelvin Cooper Lakewood-Amedex Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics, has developed a novel class of antimicrobials that operate by disrupting bacterial and fungal cell membranes, rapidly killing the microorganisms. Traditional antimicrobials work by inhibiting bacterial growth, but bacteria have evolved resistance mechanisms against all drug classes, with multidrug-resistant strains becoming increasingly common. The company is focused on treating infected diabetic foot ulcers with a topical gel formulation that locally delivers a high drug concentration while minimizing systemic side effects. Kelvin explains, "You can go back all the way to the discovery of penicillin a century ago, and there was tremendous excitement around that. And then through the 40s, when they figured out how to deep tank ferment the antibacterials, the beta lactams, as it was then, again, there was no real indication that resistance was going to be that big of a problem." "What we have done at Lakewood-Amedex Biotherapeutics is we've discovered a completely new class of antimicrobials, and it's probably good to give some context of how most antimicrobials work. Typically, what they do is they will stop the bacteria from dividing and growing, and that prevents the bacteria from causing an infection. Now the bacteria and fungi have figured out ways to mutate around that. So they have a different way of building cell walls, for example. And that has become the big problem. Our class of agents hits a completely different type of mechanism. We believe that what happens, and we have good scientific data to show this, is that this class of agents attacks the membrane of bacteria and fungi. It disrupts the membrane, which allows the contents of whatever microbe it is to spill out, and it immediately kills the bacteria extremely rapidly." #LakewoodAmedex #AntimicrobialResistance #AMR #InfectiousDiseases #Antibiotics #Antimicrobials #DiabeticFoot #DiabeticFootUlcer #HealthcareInnovation #DiabeticCare #Biotech #PublicHealth #MedicalBreakthrough $LABT /episode/index/show/empoweredpatient/id/41913325

Targeting Root Causes of Obesity and Metabolic Disease with Harith Rajagopalan Fractyl Health TRANSCRIPT 07/08/2026

Targeting Root Causes of Obesity and Metabolic Disease with Harith Rajagopalan Fractyl Health TRANSCRIPT Harith Rajagopalan, Co-Founder and CEO of Fractyl Health, is developing innovative therapies that target the root causes of obesity and metabolic diseases to achieve durable, long-lasting patient outcomes. Their drug is designed to address post-GLP-1 rebound weight gain by treating the underlying gut damage. Unlike GLP-1 medications that manage symptoms through appetite suppression, the aim is to modify the disease driving the obesity and change the paradigm from a symptomatic treatment to one of disease modification. Harith explains, "Our focus at Fractyl is all about how to achieve durable results for patients, long-lasting benefits. And the way in which we try to do so is by targeting root causes of obesity and metabolic disease and developing innovative therapies, targeting those root causes that offer the potential for long-lasting benefit for patients." "I think that GLP-1s have been transformative, as you say, but they have in many ways created an altogether new problem called post-GLP-1 rebound. What we are seeing in the United States right now is that there are a million people a month who are stopping a GLP-1. The more effective GLP-1 was for them in weight and metabolic control, the more rapidly they rebounded to whatever their weight and metabolic control were prior to treatment." "Whereas what we are doing is with our lead asset, Revita, we are targeting a root cause of obesity in the gut, a region of the gut that becomes damaged by chronic lifetime exposure to high-fat, high-sugar diets that we think is actually driving the obesity in the first place. And so if you can fix the underlying obesity, then we think that you can prevent the rebound that inevitably occurs upon the discontinuation of the medicine." #FractylHealth #Revita #Rejuva #PopulationHealth #ObesityMedicine #Endocrinology #MetabolicHealth #GLP1 #Gastroenterology #DiabetesCare #GeneTherapy /episode/index/show/empoweredpatient/id/41913245

Targeting Root Causes of Obesity and Metabolic Disease with Harith Rajagopalan Fractyl Health 07/08/2026

Targeting Root Causes of Obesity and Metabolic Disease with Harith Rajagopalan Fractyl Health Harith Rajagopalan, Co-Founder and CEO of Fractyl Health, is developing innovative therapies that target the root causes of obesity and metabolic diseases to achieve durable, long-lasting patient outcomes. Their drug is designed to address post-GLP-1 rebound weight gain by treating the underlying gut damage. Unlike GLP-1 medications that manage symptoms through appetite suppression, the aim is to modify the disease driving the obesity and change the paradigm from a symptomatic treatment to one of disease modification. Harith explains, "Our focus at Fractyl is all about how to achieve durable results for patients, long-lasting benefits. And the way in which we try to do so is by targeting root causes of obesity and metabolic disease and developing innovative therapies, targeting those root causes that offer the potential for long-lasting benefit for patients." "I think that GLP-1s have been transformative, as you say, but they have in many ways created an altogether new problem called post-GLP-1 rebound. What we are seeing in the United States right now is that there are a million people a month who are stopping a GLP-1. The more effective GLP-1 was for them in weight and metabolic control, the more rapidly they rebounded to whatever their weight and metabolic control were prior to treatment." "Whereas what we are doing is with our lead asset, Revita, we are targeting a root cause of obesity in the gut, a region of the gut that becomes damaged by chronic lifetime exposure to high-fat, high-sugar diets that we think is actually driving the obesity in the first place. And so if you can fix the underlying obesity, then we think that you can prevent the rebound that inevitably occurs upon the discontinuation of the medicine." #FractylHealth #Revita #Rejuva #PopulationHealth #ObesityMedicine #Endocrinology #MetabolicHealth #GLP1 #Gastroenterology #DiabetesCare #GeneTherapy /episode/index/show/empoweredpatient/id/41913220

Using Exosomes-Based Therapy to Restore Function After Traumatic Spinal Cord Injury with Lior Shaltiel NurExone TRANSCRIPT 07/08/2026

Using Exosomes-Based Therapy to Restore Function After Traumatic Spinal Cord Injury with Lior Shaltiel NurExone TRANSCRIPT Lior Shaltiel, CEO of NurExone, is addressing the unmet needs of those with spinal cord injuries, as current therapies only treat symptoms and do not regenerate damaged nerves from accidents or disease. The NurExone technology aims to stimulate nerve growth by targeting a protein that inhibits cell proliferation. Using exosomes, which are secreted by cells, to deliver the drug in a localized manner is possible because of the ability of the exosomes to home in on damaged tissues and cross the blood-brain barrier. Lior explains, "At the moment, the medicine can only treat it by treating the symptoms. There are a few attempts to try to regenerate the nerves that are broken and to have the reconnection of the spinal cord injury or any damage in the central nervous system. And this is a huge challenge for medicine, so far not solved. And when we solve it, we prepare to answer and give hope to so many patients, not only in spinal cord injury, but also in other injuries, such as traumatic brain injury, optic nerve, and ophthalmology. So many nerves that we have so far not been able to restore the function after the damage." "So traumatic, meaning we are talking about injury, the acute phase of a disease or illness. In most cases, let's say, spinal cord injury is due to injury, car accidents, or sports accidents. But, for example, ophthalmology, glaucoma, which is a chronic disease, can also cause damage to the optic nerve that cannot be restored. So it can be due to another illness, as a side effect of the illness, or due to injury." "So we discussed the RNA. This is one part of the technology here. Second, the technology of using our natural transmitter in our body, which is how cells communicate with each other, is called exosomes. Exosomes are tiny vesicles secreted from cells with tiny envelopes that a healthy tissue sends to a damaged tissue, a cell that is affected, or a cell that doesn't feel good. And when we understand this mechanism, we can use those exosomes as a drug delivery system." #NurExone #Exosomes #SpinalCordInjury #NeuroRegeneration #PTEN #siRNA #DrugDelivery #Neurology #RegenerativeMedicine #Nanomedicine /episode/index/show/empoweredpatient/id/41913190

Using Exosomes-Based Therapy to Restore Function After Traumatic Spinal Cord Injury with Lior Shaltiel NurExone 07/08/2026

Using Exosomes-Based Therapy to Restore Function After Traumatic Spinal Cord Injury with Lior Shaltiel NurExone Lior Shaltiel, CEO of NurExone, is addressing the unmet needs of those with spinal cord injuries, as current therapies only treat symptoms and do not regenerate damaged nerves from accidents or disease. The NurExone technology aims to stimulate nerve growth by targeting a protein that inhibits cell proliferation. Using exosomes, which are secreted by cells, to deliver the drug in a localized manner is possible because of the ability of the exosomes to home in on damaged tissues and cross the blood-brain barrier. Lior explains, "At the moment, the medicine can only treat it by treating the symptoms. There are a few attempts to try to regenerate the nerves that are broken and to have the reconnection of the spinal cord injury or any damage in the central nervous system. And this is a huge challenge for medicine, so far not solved. And when we solve it, we prepare to answer and give hope to so many patients, not only in spinal cord injury, but also in other injuries, such as traumatic brain injury, optic nerve, and ophthalmology. So many nerves that we have so far not been able to restore the function after the damage." "So traumatic, meaning we are talking about injury, the acute phase of a disease or illness. In most cases, let's say, spinal cord injury is due to injury, car accidents, or sports accidents. But, for example, ophthalmology, glaucoma, which is a chronic disease, can also cause damage to the optic nerve that cannot be restored. So it can be due to another illness, as a side effect of the illness, or due to injury." "So we discussed the RNA. This is one part of the technology here. Second, the technology of using our natural transmitter in our body, which is how cells communicate with each other, is called exosomes. Exosomes are tiny vesicles secreted from cells with tiny envelopes that a healthy tissue sends to a damaged tissue, a cell that is affected, or a cell that doesn't feel good. And when we understand this mechanism, we can use those exosomes as a drug delivery system." #NurExone #Exosomes #SpinalCordInjury #NeuroRegeneration #PTEN #siRNA #DrugDelivery #Neurology #RegenerativeMedicine #Nanomedicine /episode/index/show/empoweredpatient/id/41913175

Harnessing Conversational AI to Reduce Healthcare Workflow Friction and Clinician Burnout with Peter Swimm Toilville TRANSCRIPT 07/07/2026

Harnessing Conversational AI to Reduce Healthcare Workflow Friction and Clinician Burnout with Peter Swimm Toilville TRANSCRIPT Peter Swimm, Founder of Toilville, is a conversational AI pioneer, and he describes the transformation in healthcare resulting from the use of AI and large language models to address clinician burnout and improve patient outcomes. He emphasizes that technology should adapt to practitioners' workflows rather than forcing practitioners to change their behavior. Human oversight is essential to ensure accuracy and transparency, and Peter advocates for a culture shift where time saved through the use of AI is reinvested in higher-quality patient care and clinician satisfaction. Peter explains, "I think a lot of people think of their problems as a unique snowflake in the world. I think if we boil the ocean down to its elements, it is an understanding of the system of its inhabitants. And so we do a lot of work with small businesses and clients who typically have worked for big companies, and they've chafed at all the rules and the boundaries and the problems. They leave the big company and want to run their own show, but they lose that infrastructure." "A lot of times, they turn to tools like AI and automation, or they buy software products that don't entirely fit their thinking. And so we help them negotiate that pattern where the technology molds to what the presentation layer is and how you want to treat things and handle your data. And you don't change away from what your competitive advantage is, which is being a unique and talented person who runs the show the way they see best." "So I think the challenge is, don't let your FOMO be FAFO. Just because everyone's telling you to do AI and you don't really understand it and you don't see the positive outcomes, don't assume it's like a lack of training on your part." #SPELWork #Toilville #OptInPodcast #ResonantDiversification #AIGovernance #ResponsibleAI #ConsentFirst #DigitalHealth #HealthTech #HealthIT #ClinicalAI #HealthcareAI #PatientAdvocacy #ClinicianBurnout #HealthEquity #SDOH #AIAccountability #AIEthics #AISafety #ConsentFirst #DataSovereignty #HumanInTheLoop #HealthcareInnovation#DigitalHealth #PhysicianBurnout #HealthIT #ConversationalAI #PatientCare /episode/index/show/empoweredpatient/id/41913070

Harnessing Conversational AI to Reduce Healthcare Workflow Friction and Clinician Burnout with Peter Swimm Toilville 07/07/2026

Harnessing Conversational AI to Reduce Healthcare Workflow Friction and Clinician Burnout with Peter Swimm Toilville Peter Swimm, Founder of Toilville, is a conversational AI pioneer, and he describes the transformation in healthcare resulting from the use of AI and large language models to address clinician burnout and improve patient outcomes. He emphasizes that technology should adapt to practitioners' workflows rather than forcing practitioners to change their behavior. Human oversight is essential to ensure accuracy and transparency, and Peter advocates for a culture shift where time saved through the use of AI is reinvested in higher-quality patient care and clinician satisfaction. Peter explains, "I think a lot of people think of their problems as a unique snowflake in the world. I think if we boil the ocean down to its elements, it is an understanding of the system of its inhabitants. And so we do a lot of work with small businesses and clients who typically have worked for big companies, and they've chafed at all the rules and the boundaries and the problems. They leave the big company and want to run their own show, but they lose that infrastructure." "A lot of times, they turn to tools like AI and automation, or they buy software products that don't entirely fit their thinking. And so we help them negotiate that pattern where the technology molds to what the presentation layer is and how you want to treat things and handle your data. And you don't change away from what your competitive advantage is, which is being a unique and talented person who runs the show the way they see best." "So I think the challenge is, don't let your FOMO be FAFO. Just because everyone's telling you to do AI and you don't really understand it and you don't see the positive outcomes, don't assume it's like a lack of training on your part." #SPELWork #Toilville #OptInPodcast #ResonantDiversification #AIGovernance #ResponsibleAI #ConsentFirst #DigitalHealth #HealthTech #HealthIT #ClinicalAI #HealthcareAI #PatientAdvocacy #ClinicianBurnout #HealthEquity #SDOH #AIAccountability #AIEthics #AISafety #ConsentFirst #DataSovereignty #HumanInTheLoop #HealthcareInnovation#DigitalHealth #PhysicianBurnout #HealthIT #ConversationalAI #PatientCare /episode/index/show/empoweredpatient/id/41913060

Reformulating Diabetes Drug to Treat Degenerative Eye Diseases with Richard Garr Curative Biotechnology TRANSCRIPT 07/06/2026

Reformulating Diabetes Drug to Treat Degenerative Eye Diseases with Richard Garr Curative Biotechnology 07/06/2026

Immersive Precision Neurotherapy for Stroke and Parkinson’s Rehabilitation with Zach Henderson MindMaze Therapeutics TRANSCRIPT 06/30/2026

Immersive Precision Neurotherapy for Stroke and Parkinson’s Rehabilitation with Zach Henderson MindMaze Therapeutics TRANSCRIPT Zach Henderson, CEO at MindMaze Therapeutics, has designed a precision neurotherapeutic solution designed to offer a scalable, engaging and immersive platform for patients recovering from strokes or managing Parkinson's disease. The solution is deployed across the entire care continuum from hospital to the patient's home, providing high-intensity therapy during the neuroplastic window. The emphasis is on augmenting therapists' care by equipping them with tools to encourage therapy adherence and with data to deliver precise, personalized care. Zach explains, "So at a very high level, there are millions and millions of people across the neurology spectrum who need this type of neuro rehabilitation, neurotherapeutic solutions, either with a therapist or without, but there are only so many therapists to go around. So there's a massive supply-demand imbalance that frankly cannot be, despite the efforts of the great therapists out there, it can never be filled without resorting to technology. And that's the exact gap that we're trying to fill in the marketplace." "So MindMaze Therapeutics has a suite of solutions that are deployed across the whole continuum of care. So from acute care to the hospital to inpatient rehabilitation facilities, IRFs, to long-term acute care, to skilled nursing facilities, to outpatient, and all the way even patients taking the technology home. And then in that way, we're meeting the patient wherever they may happen to be. We're supporting the health system around the world. And importantly, we're giving therapy in this important neuroelastic window, which, in some studies, is the first 90 days following, say, a stroke, and in other studies, it goes all the way up to six months. And we're helping the health systems around the world scale their ability to treat even more patients at a very high and even improved rate." #MindMaze #ParkinsonsDisease #DigitalHealth #Neuroplasticity #PrecisionMedicine #Physiatry #Neurology #PhysicalTherapy #OccupationalTherapy #RehabInnovation #HealthTech /episode/index/show/empoweredpatient/id/41788730

Immersive Precision Neurotherapy for Stroke and Parkinson’s Rehabilitation with Zach Henderson MindMaze Therapeutics 06/30/2026

Immersive Precision Neurotherapy for Stroke and Parkinson’s Rehabilitation with Zach Henderson MindMaze Therapeutics Zach Henderson, CEO at MindMaze Therapeutics, has designed a precision neurotherapeutic solution designed to offer a scalable, engaging and immersive platform for patients recovering from strokes or managing Parkinson's disease. The solution is deployed across the entire care continuum from hospital to the patient's home, providing high-intensity therapy during the neuroplastic window. The emphasis is on augmenting therapists' care by equipping them with tools to encourage therapy adherence and with data to deliver precise, personalized care. Zach explains, "So at a very high level, there are millions and millions of people across the neurology spectrum who need this type of neuro rehabilitation, neurotherapeutic solutions, either with a therapist or without, but there are only so many therapists to go around. So there's a massive supply-demand imbalance that frankly cannot be, despite the efforts of the great therapists out there, it can never be filled without resorting to technology. And that's the exact gap that we're trying to fill in the marketplace." "So MindMaze Therapeutics has a suite of solutions that are deployed across the whole continuum of care. So from acute care to the hospital to inpatient rehabilitation facilities, IRFs, to long-term acute care, to skilled nursing facilities, to outpatient, and all the way even patients taking the technology home. And then in that way, we're meeting the patient wherever they may happen to be. We're supporting the health system around the world. And importantly, we're giving therapy in this important neuroelastic window, which, in some studies, is the first 90 days following, say, a stroke, and in other studies, it goes all the way up to six months. And we're helping the health systems around the world scale their ability to treat even more patients at a very high and even improved rate." #MindMaze #ParkinsonsDisease #DigitalHealth #Neuroplasticity #PrecisionMedicine #Physiatry #Neurology #PhysicalTherapy #OccupationalTherapy #RehabInnovation #HealthTech /episode/index/show/empoweredpatient/id/41788680

Cloud-Based Vendor-Agnostic EEG Platform Unifies and Standardizes Data with Daniele De Mari Neurogram TRANSCRIPT 06/30/2026

Cloud-Based Vendor-Agnostic EEG Platform Unifies and Standardizes Data with Daniele De Mari Neurogram TRANSCRIPT Daniele De Mari, Founder and CEO of Neurogram, points out the significant problem of non-standardized data formats in EEG (electroencephalography), compared to the universal standard used in radiology. Neurogram has developed a hardware-agnostic, cloud-based solution that standardizes EEG data from various manufacturers, integrates with EMRs, significantly improves clinical workflows, and is accessible from any computer. With improved data security and the ability to analyze large datasets, this platform can support advances in biomarker development for neurological conditions and stimulate more clinical research and collaboration. Daniele explains, "So the problem is not 100% on medical exams. It happens exclusively on EEG, and that makes it worse, because it doesn't happen everywhere, it's actually worse for EEG scans. So, knowing a parallel between EEG scans and radiology, every data point in radiology is DICON. So DICON is a universal file format that is standardized. I can send you a DICON over email or to your phone, WhatsApp, and you can open it on your phone. That's how universal it is. That's how open the file type is. It's compatible with EMRs. And so that's awesome. And that's one of the reasons why radiology grows so much. And EEG, it's an electroencephalogram. We have, I would say, 15 different brands around the world. In Brazil, we have seven. In the US, we have top like four or five companies, and they all export data in a different file format. So brand A has its own format, brand B has its own format, brand C, and so forth." "So we managed to be compatible with most of the brands out there, most of the EEG brands out there. We have a solution that is 100% agnostic and 100% in the cloud, which means we can read from multiple EEG devices out there. If you record in brand A, and I'm not going to say the brands in the podcast, but if you require data from brand A, brand B, brand C, all of it gets standardized into one unified system. So the physician no longer has to log into multiple devices in multiple systems, and it's all in one place. As I said, it's 100% in the cloud, so they can access from a Mac computer, which is now impossible to read EEGs from a Mac computer. Now you can do this. It's compliant. It's HIPAA compliant. We're moving towards the FDA approval process right now for the system, although we're actually selling in Brazil." #Neurogram #EEG #HealthcareIT #ClinicalNeurophysiology #DigitalHealth #HealthDataStandardization #EMRIntegration #MedicalAI #PatientSafety #HealthcareInnovation /episode/index/show/empoweredpatient/id/41807305

Cloud-Based Vendor-Agnostic EEG Platform Unifies and Standardizes Data with Daniele De Mari Neurogram 06/30/2026

Cloud-Based Vendor-Agnostic EEG Platform Unifies and Standardizes Data with Daniele De Mari Neurogram Daniele De Mari, Founder and CEO of Neurogram, points out the significant problem of non-standardized data formats in EEG (electroencephalography), compared to the universal standard used in radiology. Neurogram has developed a hardware-agnostic, cloud-based solution that standardizes EEG data from various manufacturers, integrates with EMRs, significantly improves clinical workflows, and is accessible from any computer. With improved data security and the ability to analyze large datasets, this platform can support advances in biomarker development for neurological conditions and stimulate more clinical research and collaboration. Daniele explains, "So the problem is not 100% on medical exams. It happens exclusively on EEG, and that makes it worse, because it doesn't happen everywhere, it's actually worse for EEG scans. So, knowing a parallel between EEG scans and radiology, every data point in radiology is DICON. So DICON is a universal file format that is standardized. I can send you a DICON over email or to your phone, WhatsApp, and you can open it on your phone. That's how universal it is. That's how open the file type is. It's compatible with EMRs. And so that's awesome. And that's one of the reasons why radiology grows so much. And EEG, it's an electroencephalogram. We have, I would say, 15 different brands around the world. In Brazil, we have seven. In the US, we have top like four or five companies, and they all export data in a different file format. So brand A has its own format, brand B has its own format, brand C, and so forth." "So we managed to be compatible with most of the brands out there, most of the EEG brands out there. We have a solution that is 100% agnostic and 100% in the cloud, which means we can read from multiple EEG devices out there. If you record in brand A, and I'm not going to say the brands in the podcast, but if you require data from brand A, brand B, brand C, all of it gets standardized into one unified system. So the physician no longer has to log into multiple devices in multiple systems, and it's all in one place. As I said, it's 100% in the cloud, so they can access from a Mac computer, which is now impossible to read EEGs from a Mac computer. Now you can do this. It's compliant. It's HIPAA compliant. We're moving towards the FDA approval process right now for the system, although we're actually selling in Brazil." #Neurogram #EEG #HealthcareIT #ClinicalNeurophysiology #DigitalHealth #HealthDataStandardization #EMRIntegration #MedicalAI #PatientSafety #HealthcareInnovation /episode/index/show/empoweredpatient/id/41787885

Autonomous Asynchronous Robots for Secure Medical Sample Transport with Dan O’Toole Arrive AI TRANSCRIPT 06/30/2026

Autonomous Asynchronous Robots for Secure Medical Sample Transport with Dan O’Toole Arrive AI TRANSCRIPT Dan O'Toole, Founder and CEO of Arrive AI, is bringing asynchronous autonomous delivery systems to healthcare environments, enabling robots and drones to make deliveries without the recipient needing to be present. The goal is to automate logistical tasks to solve major inefficiencies in hospitals, freeing skilled workers from moving samples and supplies, which in turn improves the quality of care and reduces clinician burnout. The system is presented as a way to make processes better, faster, fresher, cheaper, greener, and safer by eliminating bottlenecks and ensuring sample integrity through features such as temperature control and a security chain of custody. Dan explains, "I love that you started out with the term asynchronous. Nobody ever even knows what that is. So I applaud you. Thank you. That is the key to autonomy. Without it, you're not unlocking the full value of autonomy. So basically here at Arrive AI what we are doing is we're building the next network and platform to support and scale all kinds of autonomous delivery, whether it's robots, drones, unmanned vehicles, and still supporting conventional delivery, UPS, US Postal Service, and others. So we're excited about that." "But right now, anytime autonomous delivery happens, two things have to happen. You have to be there to meet the mode of delivery, and it has to be there to meet you. When you have an Arrive Point™ in that ecosystem, you've unlocked all the value of autonomous delivery because now the robot can beat you there. It can drop off the item that you're expecting at your Arrive Point and go on to its next mission without being held up." #ArriveAI #AutonomousDelivery #HealthcareInnovation #HospitalRobotics #FutureOfHealthcare #DroneDelivery #HospitalOperations #ClinicalWorkflow #DigitalHealth #PatientSafety #LabMedicine #HealthcareLogistics #AIinHealthcare /episode/index/show/empoweredpatient/id/41786685

Autonomous Asynchronous Robots for Secure Medical Sample Transport with Dan O’Toole Arrive AI 06/30/2026

Autonomous Asynchronous Robots for Secure Medical Sample Transport with Dan O’Toole Arrive AI Dan O'Toole, Founder and CEO of Arrive AI, is bringing asynchronous autonomous delivery systems to healthcare environments, enabling robots and drones to make deliveries without the recipient needing to be present. The goal is to automate logistical tasks to solve major inefficiencies in hospitals, freeing skilled workers from moving samples and supplies, which in turn improves the quality of care and reduces clinician burnout. The system is presented as a way to make processes better, faster, fresher, cheaper, greener, and safer by eliminating bottlenecks and ensuring sample integrity through features such as temperature control and a security chain of custody. Dan explains, "I love that you started out with the term asynchronous. Nobody ever even knows what that is. So I applaud you. Thank you. That is the key to autonomy. Without it, you're not unlocking the full value of autonomy. So basically here at Arrive AI what we are doing is we're building the next network and platform to support and scale all kinds of autonomous delivery, whether it's robots, drones, unmanned vehicles, and still supporting conventional delivery, UPS, US Postal Service, and others. So we're excited about that." "But right now, anytime autonomous delivery happens, two things have to happen. You have to be there to meet the mode of delivery, and it has to be there to meet you. When you have an Arrive Point™ in that ecosystem, you've unlocked all the value of autonomous delivery because now the robot can beat you there. It can drop off the item that you're expecting at your Arrive Point and go on to its next mission without being held up." #ArriveAI #AutonomousDelivery #HealthcareInnovation #HospitalRobotics #FutureOfHealthcare #DroneDelivery #HospitalOperations #ClinicalWorkflow #DigitalHealth #PatientSafety #LabMedicine #HealthcareLogistics #AIinHealthcare /episode/index/show/empoweredpatient/id/41786425

Advanced Molecular Diagnostics Transform Skin Cancer Risk Stratification with Dr. Matthew Goldberg Castle Biosciences TRANSCRiPT 06/29/2026

Advanced Molecular Diagnostics Transform Skin Cancer Risk Stratification with Dr. Matthew Goldberg Castle Biosciences TRANSCRiPT Dr. Matthew Goldberg, Senior Vice President for Medical at Castle Biosciences, discusses the uncertainty clinicians face when determining treatments for skin cancer due to the limitations of traditional pathology reports. Castle's gene expression profile tests were developed to improve the accuracy of risk stratification for patients with cutaneous melanoma and high-risk cutaneous squamous cell carcinoma. These tests provide prognostic information by analyzing the tumor's RNA, offering more granular and accurate risk assessment and informing about the intensity of follow-up and long-term risk management strategies. Matthew explains, "So this is an important topic for dermatologists who are really on the front lines of skin cancer diagnosis and management for patients who are confronting skin cancer today. I'm a board-certified dermatologist and dermatopathologist by training. And to me, I think that the core uncertainty is centered around some of the known limitations around the prognostic accuracy of pathology. That's kind of worth unpacking here, but I think what it comes down to is that dermatologists are involved in identifying concerning skin lesions, identifying and, through biopsy, taking a skin sample, and finding skin cancers." "Dermatopathologists are the collaborative colleagues who interpret the skin biopsy samples and return the pathological diagnoses to the dermatologist. For the treating clinician, the key task is to understand the implications of the types of skin cancers identified in this process to determine the most appropriate, risk-aligned downstream management for patients with these skin cancers." "So Castle Biosciences has developed a range of tests that are really focused on impactful skin cancers that are some of the biggest challenges for dermatologists and the patients that we serve in the clinic, specifically around cutaneous melanoma with the DecisionDx-Melanoma gene expression profile test and also high-risk cutaneous squamous cell carcinomas with the DecisionDx-SCC test." #CastleBiosciences #SkinCancer #CancerCare #HealthcareInnovation #Dermatology #MolecularDiagnostics #PrecisionMedicine #RiskStratification #ClinicalDecisionMaking #DigitalPathology #Oncology #Melanoma #SquamousCellCarcinoma #GeneExpression #SharedDecisionMaking /episode/index/show/empoweredpatient/id/41785600

Advanced Molecular Diagnostics Transform Skin Cancer Risk Stratification with Dr. Matthew Goldberg Castle Biosciences 06/29/2026

Advanced Molecular Diagnostics Transform Skin Cancer Risk Stratification with Dr. Matthew Goldberg Castle Biosciences Dr. Matthew Goldberg, Senior Vice President for Medical at Castle Biosciences, discusses the uncertainty clinicians face when determining treatments for skin cancer due to the limitations of traditional pathology reports. Castle's gene expression profile tests were developed to improve the accuracy of risk stratification for patients with cutaneous melanoma and high-risk cutaneous squamous cell carcinoma. These tests provide prognostic information by analyzing the tumor's RNA, offering more granular and accurate risk assessment and informing about the intensity of follow-up and long-term risk management strategies. Matthew explains, "So this is an important topic for dermatologists who are really on the front lines of skin cancer diagnosis and management for patients who are confronting skin cancer today. I'm a board-certified dermatologist and dermatopathologist by training. And to me, I think that the core uncertainty is centered around some of the known limitations around the prognostic accuracy of pathology. That's kind of worth unpacking here, but I think what it comes down to is that dermatologists are involved in identifying concerning skin lesions, identifying and, through biopsy, taking a skin sample, and finding skin cancers." "Dermatopathologists are the collaborative colleagues who interpret the skin biopsy samples and return the pathological diagnoses to the dermatologist. For the treating clinician, the key task is to understand the implications of the types of skin cancers identified in this process to determine the most appropriate, risk-aligned downstream management for patients with these skin cancers." "So Castle Biosciences has developed a range of tests that are really focused on impactful skin cancers that are some of the biggest challenges for dermatologists and the patients that we serve in the clinic, specifically around cutaneous melanoma with the DecisionDx-Melanoma gene expression profile test and also high-risk cutaneous squamous cell carcinomas with the DecisionDx-SCC test." #CastleBiosciences #SkinCancer #CancerCare #HealthcareInnovation #Dermatology #MolecularDiagnostics #PrecisionMedicine #RiskStratification #ClinicalDecisionMaking #DigitalPathology #Oncology #Melanoma #SquamousCellCarcinoma #GeneExpression #SharedDecisionMaking /episode/index/show/empoweredpatient/id/41785305

Empowered Patient Podcast

TOPICS